Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar

Yunhee Chang, Seoyong Kim, Yeun Kim, Phyu Win Ei, Dasom Hwang, Jongseok Lee, Chulhun L. Chang, Hyeyoung Lee

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Although the incidence of tuberculosis (TB) is decreasing, cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB continue to increase. As conventional phenotype drug susceptibility testing (pDST) takes six to eight weeks, molecular assays are widely used to determine drug resistance. we developed QuantaMatrix Multiplexed Assay Platform (QMAP) MDR/XDR assay (QuantaMatrix Inc., Seoul, Korea) that can simultaneously detect mutations related to both first- and second-line drug resistance (rifampin, isoniazid, ethambutol, fluoroquinolones, second-line injectable drugs, and streptomycin). METHODS: We used 190 clinical Mycobacterium tuberculosis (MTB) strains isolated from Myanmar, compared QMAP and pDST results, and determined concordance rates. Additionally, we performed sequence analyses for discordant results. RESULTS: QMAP results were 87.9% (167/190) concordant with pDST results. In the 23 isolates with discordant results, the QMAP and DNA sequencing results completely matched. CONCLUSIONS: The QMAP MDR/XDR assay can detect all known DNA mutations associated with drug resistance for both MDR- and XDR-MTB strains. It can be used for molecular diagnosis of MDR- and XDR-TB to rapidly initiate appropriate anti-TB drug therapy.

Original languageEnglish
Pages (from-to)142-147
Number of pages6
JournalAnnals of laboratory medicine
Volume40
Issue number2
DOIs
Publication statusPublished - 2020 Mar 1

Fingerprint

Extensively Drug-Resistant Tuberculosis
Myanmar
Assays
Drug Resistance
Multidrug-Resistant Tuberculosis
Phenotype
Mycobacterium tuberculosis
Pharmaceutical Preparations
Tuberculosis
Ethambutol
Mutation
Fluoroquinolones
Isoniazid
Streptomycin
Rifampin
Korea
DNA Sequence Analysis
Sequence Analysis
Testing
Drug therapy

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Chang, Yunhee ; Kim, Seoyong ; Kim, Yeun ; Ei, Phyu Win ; Hwang, Dasom ; Lee, Jongseok ; Chang, Chulhun L. ; Lee, Hyeyoung. / Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar. In: Annals of laboratory medicine. 2020 ; Vol. 40, No. 2. pp. 142-147.
@article{0904381256744566a170c3946fe6b016,
title = "Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar",
abstract = "BACKGROUND: Although the incidence of tuberculosis (TB) is decreasing, cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB continue to increase. As conventional phenotype drug susceptibility testing (pDST) takes six to eight weeks, molecular assays are widely used to determine drug resistance. we developed QuantaMatrix Multiplexed Assay Platform (QMAP) MDR/XDR assay (QuantaMatrix Inc., Seoul, Korea) that can simultaneously detect mutations related to both first- and second-line drug resistance (rifampin, isoniazid, ethambutol, fluoroquinolones, second-line injectable drugs, and streptomycin). METHODS: We used 190 clinical Mycobacterium tuberculosis (MTB) strains isolated from Myanmar, compared QMAP and pDST results, and determined concordance rates. Additionally, we performed sequence analyses for discordant results. RESULTS: QMAP results were 87.9{\%} (167/190) concordant with pDST results. In the 23 isolates with discordant results, the QMAP and DNA sequencing results completely matched. CONCLUSIONS: The QMAP MDR/XDR assay can detect all known DNA mutations associated with drug resistance for both MDR- and XDR-MTB strains. It can be used for molecular diagnosis of MDR- and XDR-TB to rapidly initiate appropriate anti-TB drug therapy.",
author = "Yunhee Chang and Seoyong Kim and Yeun Kim and Ei, {Phyu Win} and Dasom Hwang and Jongseok Lee and Chang, {Chulhun L.} and Hyeyoung Lee",
year = "2020",
month = "3",
day = "1",
doi = "10.3343/alm.2020.40.2.142",
language = "English",
volume = "40",
pages = "142--147",
journal = "Annals of Laboratory Medicine",
issn = "2234-3806",
publisher = "Seoul National University",
number = "2",

}

Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar. / Chang, Yunhee; Kim, Seoyong; Kim, Yeun; Ei, Phyu Win; Hwang, Dasom; Lee, Jongseok; Chang, Chulhun L.; Lee, Hyeyoung.

In: Annals of laboratory medicine, Vol. 40, No. 2, 01.03.2020, p. 142-147.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar

AU - Chang, Yunhee

AU - Kim, Seoyong

AU - Kim, Yeun

AU - Ei, Phyu Win

AU - Hwang, Dasom

AU - Lee, Jongseok

AU - Chang, Chulhun L.

AU - Lee, Hyeyoung

PY - 2020/3/1

Y1 - 2020/3/1

N2 - BACKGROUND: Although the incidence of tuberculosis (TB) is decreasing, cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB continue to increase. As conventional phenotype drug susceptibility testing (pDST) takes six to eight weeks, molecular assays are widely used to determine drug resistance. we developed QuantaMatrix Multiplexed Assay Platform (QMAP) MDR/XDR assay (QuantaMatrix Inc., Seoul, Korea) that can simultaneously detect mutations related to both first- and second-line drug resistance (rifampin, isoniazid, ethambutol, fluoroquinolones, second-line injectable drugs, and streptomycin). METHODS: We used 190 clinical Mycobacterium tuberculosis (MTB) strains isolated from Myanmar, compared QMAP and pDST results, and determined concordance rates. Additionally, we performed sequence analyses for discordant results. RESULTS: QMAP results were 87.9% (167/190) concordant with pDST results. In the 23 isolates with discordant results, the QMAP and DNA sequencing results completely matched. CONCLUSIONS: The QMAP MDR/XDR assay can detect all known DNA mutations associated with drug resistance for both MDR- and XDR-MTB strains. It can be used for molecular diagnosis of MDR- and XDR-TB to rapidly initiate appropriate anti-TB drug therapy.

AB - BACKGROUND: Although the incidence of tuberculosis (TB) is decreasing, cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB continue to increase. As conventional phenotype drug susceptibility testing (pDST) takes six to eight weeks, molecular assays are widely used to determine drug resistance. we developed QuantaMatrix Multiplexed Assay Platform (QMAP) MDR/XDR assay (QuantaMatrix Inc., Seoul, Korea) that can simultaneously detect mutations related to both first- and second-line drug resistance (rifampin, isoniazid, ethambutol, fluoroquinolones, second-line injectable drugs, and streptomycin). METHODS: We used 190 clinical Mycobacterium tuberculosis (MTB) strains isolated from Myanmar, compared QMAP and pDST results, and determined concordance rates. Additionally, we performed sequence analyses for discordant results. RESULTS: QMAP results were 87.9% (167/190) concordant with pDST results. In the 23 isolates with discordant results, the QMAP and DNA sequencing results completely matched. CONCLUSIONS: The QMAP MDR/XDR assay can detect all known DNA mutations associated with drug resistance for both MDR- and XDR-MTB strains. It can be used for molecular diagnosis of MDR- and XDR-TB to rapidly initiate appropriate anti-TB drug therapy.

UR - http://www.scopus.com/inward/record.url?scp=85074072581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074072581&partnerID=8YFLogxK

U2 - 10.3343/alm.2020.40.2.142

DO - 10.3343/alm.2020.40.2.142

M3 - Article

C2 - 31650730

AN - SCOPUS:85074072581

VL - 40

SP - 142

EP - 147

JO - Annals of Laboratory Medicine

JF - Annals of Laboratory Medicine

SN - 2234-3806

IS - 2

ER -